详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Li, Jin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] * ; Qin, Shukui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Bai, Yuxian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Deng, Yanhong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Yang, Lei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Xu, Rui-Hua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Chen, Zhendong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhong, Haijun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Pan, Hongming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Shu, Yonggian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Yuan, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Xu, Nong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhou, Jianfeng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Liu, Tianshu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Ma, Dong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Wu, Changping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Cheng, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Fan, Songhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Hua, Ye[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Su, Weiguo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ;

机构： [1]Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai, Peoples R China [2]PLA 81 Hosp, Nanjing, Peoples R China [3]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [4]Sun Yat Sen Univ, Hosp Affiliated 6, Dept Med Oncol, Guangzhou, Peoples R China [5]Nantong Tumor Hosp, Nantong, Peoples R China [6]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China [7]Anhui Med Univ, Hosp 2, Hefei, Peoples R China [8]Zhejiang Canc Hosp, Hangzhou, Peoples R China [9]Sir Run Run Shaw Hosp, Hangzhou, Peoples R China [10]Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China [11]Zhejiang Univ, Hosp 2, Hangzhou, Peoples R China [12]Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China [13]Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China [14]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [15]Guangdong Gen Hosp, Guangzhou, Peoples R China [16]Soochow Univ, Affiliated Hosp 3, Dept Oncol, Changzhou, Peoples R China [17]Jilin Canc Hosp, Changchun, Peoples R China [18]Hutchis MediPharma Ltd, Shanghai, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

第一作者：

第一作者机构： [1]Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai, Peoples R China [2]PLA 81 Hosp, Nanjing, Peoples R China [3]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [4]Sun Yat Sen Univ, Hosp Affiliated 6, Dept Med Oncol, Guangzhou, Peoples R China [5]Nantong Tumor Hosp, Nantong, Peoples R China [6]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China [7]Anhui Med Univ, Hosp 2, Hefei, Peoples R China [8]Zhejiang Canc Hosp, Hangzhou, Peoples R China [9]Sir Run Run Shaw Hosp, Hangzhou, Peoples R China [10]Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China [11]Zhejiang Univ, Hosp 2, Hangzhou, Peoples R China [12]Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China [13]Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China [14]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [15]Guangdong Gen Hosp, Guangzhou, Peoples R China [16]Soochow Univ, Affiliated Hosp 3, Dept Oncol, Changzhou, Peoples R China [17]Jilin Canc Hosp, Changchun, Peoples R China [18]Hutchis MediPharma Ltd, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).

文献详情